The first-line treatment of Helicobacter pylori infection in Piedmont in the year 2017

Panminerva Med. 2017 Jun;59(2):199. doi: 10.23736/S0031-0808.17.03291-8. Epub 2017 Jan 17.

Authors

Rinaldo Pellicano¹, Davide G Ribaldone², Sharmila Fagoonee³, Marco Astegiano², Giorgio M Saracco^{2

4}

Affiliations

¹ Unit of Gastroenterology, Molinette Hospital, Turin, Italy - rinaldo_pellican@hotmail.com.
² Unit of Gastroenterology, Molinette Hospital, Turin, Italy.
³ Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center, University of Turin, Turin, Italy.
⁴ Department of Oncology, University of Turin, Turin, Italy.

PMID: 28094491
DOI: 10.23736/S0031-0808.17.03291-8

No abstract available

Publication types

Comment

MeSH terms

Amoxicillin
Anti-Bacterial Agents
Drug Therapy, Combination
Helicobacter Infections*
Helicobacter pylori*
Humans

Substances

Anti-Bacterial Agents
Amoxicillin